

Clinical Criteria Updates

Summary: On May 20, 2022, August 19, 2022, and September 22, 2022, the Pharmacy and Therapeutic (P&T) Committee approved the following *Clinical Criteria* applicable to the medical drug benefit for Empire BlueCross BlueShield HealthPlus (Empire). These policies were developed, revised or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. For questions or additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other providers in your practice and office staff.

Please note:

- The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Empire only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective date	Document number	Clinical Criteria title	New or revised
April 6, 2023	*ING-CC-0018	Pompe Disease	Revised
April 6, 2023	*ING-CC-0017	Xiaflex (collagenase clostridium histolyticum)	Revised
April 6, 2023	ING-CC-0174	Kesimpta (ofatumumab)	Revised
April 6, 2023	ING-CC-0089	Mozobil (plerixafor)	Revised
April 6, 2023	ING-CC-0158	Enhertu (fam-trastuzumab deruxtecan-nxki)	Revised
April 6, 2023	ING-CC-0130	Imfinzi (durvalumab)	Revised
April 6, 2023	ING-CC-0097	Vidaza (azacitidine)	Revised
April 6, 2023	*ING-CC-0072	Vascular Endothelial Growth Factor Inhibitors	Revised
April 6, 2023	ING-CC-0063	Stelara (ustekinumab)	Revised
April 6, 2023	*ING-CC-0002	Colony Stimulating Factor Agents	Revised

Effective date	Document number	Clinical Criteria title	New or revised
April 6, 2023	*ING-CC-0107	Bevacizumab for non-ophthalmologic indications	Revised
April 6, 2023	*ING-CC-0166	Trastuzumab Agents	Revised



Email is the quickest and most direct way to receive important information from Empire BlueCross BlueShield HealthPlus.

To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (<https://bit.ly/3zqQdYB>).

